SecBot SecBot
COURT-RULING ·Filed Sep 10, 2026

BIO

BIO-RAD LABORATORIES, INC.
BEARISH
Impact 5/10
Horizonmonths Processed2mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight ▼ Bearish

This procedural ruling keeps the case alive but does not establish liability or damages. Monitor for discovery milestones and any settlement discussions. The 10X Genomics settlement sublicense and Quanterix correspondence are key factual disputes that could drive materiality if the case proceeds to summary judgment or trial.

DirectionBearish
Confidencemedium
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$369.32
T+0 close · Sep 11, 2026 · via day close
Latest settled
−0.86%
T+20 · $366.16 · next T+60 in 20d
Vs SPY
−2.72%
α at T+20
Latest observation
+1.52%
T+46 · FF3 residual α
  1. T+0 · Sep 11 $369.32entry
  2. T+1 · 2mo ago −0.21%α +0.24% · $368.55
  3. T+5 · 2mo ago +1.92%α +2.26% · $376.41
  4. T+20 · 6w ago −0.86%α −2.72% · $366.16
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The court granted Brandeis University leave to file a Second Amended Complaint against Bio-Rad, allowing new allegations that Bio-Rad failed to notify Brandeis about Quanterix's infringement of licensed patents for ~7.5 years, potentially depriving Brandeis of ~1.5 years of patent damages. Bio-Rad's motion to dismiss was denied as moot. This is an early-stage procedural ruling (motion for leave to amend) that keeps the case alive but does not resolve any liability or damages, a modest negative for Bio-Rad as litigation risk persists, but the financial exposure remains unquantified and the ruling is not a merits determination.

Court Ruling Details

Ruling Date
Sep 10, 2026
Court
United States District Court for the District of Massachusetts
Court Level
District
Judge
Angel Kelley
Case Type
contract
Ruling Type
procedural
Outcome
PARTIAL: mixed ruling, some claims won/lost
Precedent Risk
LOW

Key Facts

  • Court granted Brandeis University's motion to file a Second Amended Complaint against Bio-Rad.
  • New allegations include Bio-Rad's failure to notify Brandeis of Quanterix's infringement of licensed patents for approximately 7.5 years.
  • Alleged delay may have deprived Brandeis of ~1.5 years of patent damages (statutory 6-year lookback limit).
  • Bio-Rad's motion to dismiss was denied as moot; the case continues.
  • No damages have been awarded or quantified in this ruling, it is a procedural order on pleading amendments.
  • The underlying license agreement covers patents related to droplet-based digital PCR technology, a core area for Bio-Rad.

Financial Impact

No damages awarded or quantified in this ruling. Potential exposure from royalty underpayments, settlement proceeds from 10X Genomics dispute, and Chapter 93A claims remains unquantified in the document.

royalty revenuelegal expensescontingent liabilities

Risk Factors

  • Adverse judgment on breach of contract and Chapter 93A claims could result in damages including unpaid royalties, settlement proceeds from 10X Genomics, and potential treble damages under Massachusetts law.
  • Litigation overhang may distract management and create uncertainty around Bio-Rad's IP licensing practices and digital PCR product line.
  • Discovery could reveal additional instances of non-compliance or expand the scope of alleged breaches.

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
50% bullish (10 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-abc9bd02d2-BIO

Track record

9 reports on BIO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $370.48 Now $360.26 −2.76% settles Nov 19
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $386.00 Now $360.26 −6.67% settles Nov 18
  3. Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
  5. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $388.31 to $360.26 Now $360.26 +7.22% ▲ +7.22% +5.53% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $369.00 to $370.48 Now $360.26 −2.37% ▲ +0.40% −2.89% vs SPY
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $385.12 to $379.99 Now $360.26 −6.46% ▼ −1.33% −0.62% vs SPY
  8. Sep 10, 20269w ago Court Ruling Bearish 5/10 Viewing Entry $369.32 to $376.41 Now $360.26 +2.45% ▼ −1.92% −2.26% vs SPY
  9. Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $285.94 to $282.44 Now $360.26 +25.99% ▼ −1.22% −1.90% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 4m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Sep 11, 2026